Summary

Eligibility
for people ages 18-90 (full criteria)
Location
at Torrance, California
Dates
study started
completion around
Principal Investigator
by William W Stringer, MD

Description

Summary

The purpose of the study is to assess the physiologic, immunologic, and mental health effects of a rehabilitation program on patients with Long Haul COVID (LHC).

Official Title

Long Haul COVID Rehabilitation Research Program

Details

1.0 Objectives 1.1 Describe the purpose, specific aims, or objectives.

The purpose is to assess the physiologic, immunologic, and mental health effects of a rehabilitation program on patients with Long Haul COVID (LHC).

1.2 State the hypotheses to be tested.

Long Haul COVID Patients who enroll and complete a 10 week program of Physiologic and Psychological Rehabilitation will have reduced Long Haul COVID Symptoms, Improved Physical Status, Reduced Inflammatory Markers, and Augmented Psychological Well Being.

Keywords

Long Haul COVID or Post Acute Sequella of COVID - PASC (U09.9), Post-Acute COVID-19 Syndrome, Virtual vs On Site Pulmonary Rehabilitation

Eligibility

You can join if…

Open to people ages 18-90

  • Long Haul COVID Infection (Documented by PCR or patient report)
  • Age >= 18 years old.
  • At least 12 weeks since the initial COVID Infection.
  • One or more of the following symptom/signs: Fatigue, Dyspnea, Exercise Intolerance, Post Exertional Malaise and/or Difficulty Breathing.
  • Able to perform a cardiopulmonary exercise test.

You CAN'T join if...

  • Patients is not able to perform technically acceptable pulmonary function tests and symptom-limited cardiopulmonary cycle ergometry tests.
  • Patients who desaturate to SpO2 <80% on screening incremental exercise testing.
  • Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the screening visit or patients who are currently in a pulmonary rehabilitation program.
  • Patients who have taken an investigational drug within one month or six half-lives (whichever is greater) prior to screening visit (Visit 1).
  • Pregnant or nursing women.
  • Women of childbearing potential who are not using a highly effective method of birth control. Female patients will be considered of childbearing potential unless surgically sterilized by hysterectomy or bilateral tubal ligation, or post-menopausal for at least two years.
  • Patients who are currently participating in another interventional study.
  • Malignancy for which the patient has undergone resection, radiation therapy, or chemotherapy within the last 2 years
  • Any other significant disease than COVID which, in the opinion of the investigator, may i) put the patient at risk because of participation in the study, ii) influence the results of the study (e.g. Insulin or testosterone therapy, systemic corticosteroids, HIV, etc), iii) cause concern regarding the patient's ability to participate in the study.

Location

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center accepting new patients
    Torrance California 90509 United States

Lead Scientist at UCLA

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
ID
NCT05398692
Study Type
Interventional
Participants
Expecting 40 study participants
Last Updated